The clinical course and short-term health outcomes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center

Betül Sözeri, Şengül Çağlayan, Vildan Atasayan, Kadir Ulu, Özge Pelin Akbay, Canan Hasbal Akkus, Gürkan Atay, Enes Sali, Mehmet Karacan, Taliha Öner, Seher Erdoğan, and Ferhat Demir

ABSTRACT

Objectives: Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe condition resulting in excessive response of the immune system after SARS-CoV-2 infection. We report a single-center cohort of children with MIS-C, describing the spectrum of presentation, therapies, clinical course, and short-term outcomes.

Methods: This is a prospective observational study from a tertiary pediatric rheumatology center including patients (aged 1 month to 21 years) diagnosed with MIS-C between April 2020 to April 2021. Demographic, clinical, laboratory results, and follow-up were collected through the electronic patient record system and analyzed.

Results: A total of 67 patients with MIS-C were included in the study. Fever was detected in all patients; gastrointestinal system symptoms were found in 67.2% of the patients, rash in 38.8%, conjunctivitis in 31.3%, hypotension in 26.9%, and/or pericarditis in 22.4%, respectively. Respiratory symptoms were only in five patients (7.5%). Kawasaki Disease like presentation was found in 37.3% of the patients. The mean duration of hospitalization was 11.8 ± 7.07 days. Fifty-seven patients (85%) received intravenous immunoglobulin (IVIG), 45 (67%) received corticosteroids, 17 (25.3%) received anakinra, and one (1.5%) received tocilizumab. Seven of the patients (10.4%) underwent therapeutic plasma exchange (TPE). In 21 (31.3%) patients, a pediatric intensive care unit (PICU) was required in a median of 2 days. The first finding to improve was fever, while the first parameter to decrease was ferritin (median 6.5 days [IQR, 4–11.2 days]). Sixty-five patients were discharged home with a median hospital stay of 10 days (IQR, 7–15 days).

Conclusion: Patients with MIS-C may have severe cardiac findings and intensive care requirements in admission and hospital follow-up. The vast majority of these findings improve with effective treatment without any sequelae until discharge and in a short time in follow-up. Although the pathogenesis and treatment plan of the disease are partially elucidated, follow-up studies are needed in terms of long-term prognosis and relapse probabilities.

INTRODUCTION

The coronavirus 2019 (COVID-19) outbreak has caused major changes in daily life and routine activities in societies all over the world. Fortunately, SARS-CoV-2 often causes mild illness in children. Multisystem inflammatory syndrome in children (MIS-C) and MIS-N in the newborn is a rare but severe condition resulting in excessive response of the immune system after SARS-CoV-2 infection. Overall, MIS-C is a rare complication of SARS-CoV-2. In the multicenter study, COVID-19 reported an incidence of MIS-C of 0.14% in children with infection [1]. Although MIS-C occurs in a wide age spectrum from infancy to young adulthood, it is typically reported at school age [2–6]. MIS-C is a life-threatening condition that is characterized by severe inflammation of one or more parts of the body, particularly the lungs, heart, and gastrointestinal tract. It begins several weeks after exposure to SARS-CoV-2. Then patients with MIS-C have symptoms of persistent fever, often accompanied by gastrointestinal symptoms (abdominal pain, vomiting, diarrhea), mucocutaneous changes (rash, conjunctivitis), and cardiac changes (myocarditis, left ventricular dysfunction). Rarely, neurological symptoms (headache, meningismus) have been reported in patients [2–7]. MIS-C signs and symptoms that occur in children may overlap with other time-sensitive diagnoses, such as sepsis, toxic shock syndrome, Kawasaki disease (KD), macrophage activation syndrome, appendicitis, or meningitis. MIS-C patients had a negative PCR for SARS-CoV-2, while they had positive antibody test results [4,8,9].
MIS-C is characterized by a cytokine storm, which is caused by unconventional T cell activation, resulting in intense activation of other immune cells and the release of cytokines, such as interleukins (IL-1,6,18), TNF-α and INF-gamma [10]. Also, MIS-C shows findings like Toxic shock syndrome, hemophagocytic lymphohytosis (HLH) or macrophage activation syndrome (MAS) observed in various rheumatic disorders, such as systemic juvenile idiopathic arthritis [10,11].

The fact that hyperinflammatory or cytokine storm develops after infection or by delayed parainfectious mechanism in MIS-C supports the existence of nonspecific T cell activation, autoantibodies, immunocomplexes, and antibody-dependent enhancement of immune reactions in disease pathogenesis [9,12–14].

The long-term prognosis of MIS-C is unknown. According to previous reports, median length of stay in hospital is 7 days, need for intensive care in 68% of the patients and mortality rate is 1.7% [15]. In a study conducted with a small number of patients, it was reported that cardiac involvement observed during the follow-up period improved in most of the patients [16]. We report a single-center cohort of children with MIS-C, describing the spectrum of presentation, therapies, clinical course, and short-term outcomes.

Materials and methods

This is a prospective observational study of pediatric patients (aged 1 month to 21 years) with a confirmed infection with SARS-CoV-2 who meet criteria for MIS-C admitted from April 2020 to April 2021, to a tertiary pediatric rheumatology center. The study protocol was reviewed and approved by the Ethics Committee (EC) of the University of Health Sciences, Umraniye Training and Research Hospital (Approval No: B.10.1TKH.4.34.H.GP.0.01/9) with the ethical principles laid down in the Declaration of Helsinki. Five patients were reported previously described in a recently published letter [17].

A confirmed case of COVID-19 was defined as a positive result from real-time reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal swab for SARS-CoV-2 or positive SARS-CoV-2 antibody assay or exposure with patients with COVID-19.

The Centers for Disease Control and Prevention case definition for MIS-C was used to define a confirmed case of MIS-C [18]. Demographic, clinical, laboratory results and follow-up data were collected through the electronic patient record system.

The Statistical Package for the Social Sciences (SPSS) (version 26.0, SPSS-Inc., Chicago, IL, USA) was used for statistical analysis. The normality of the distribution of the variables was assessed by visual (histogram, probability plots) and analytic methods (Kolmogorov-Smirnov/Shapiro-Wilk’s test). Descriptive analyses were presented as percentages, mean ± standard deviation, medians, minimum (min), maximum (max), and interquartile range (IQR) values. A p value < 0.05 was considered as statistically significant.

Results

A total of 67 patients with MIS-C were included. The median follow-up time was 3 months (IQR, 2–4 months). Mean age was 9 ± 5.2 years (min -max: 1–18 years) and 71.6% (n = 48) were male. Comorbid diseases were detected in 32.8% of the patients (n = 12). 75% of these 12 patients were obesity (n = 9), 50% (n = 6) autoimmune or autoinflammatory disease, 17% (n = 2) immunodeficiency and 17% (n = 2) epilepsy.

Fever was detected in all patients; mean duration of fever was 4.4 days (min-max: 1–15 days). 59.7% of the patients (n = 40) had fever for more than four days at the time of admission. The second most common symptoms of presentation were gastrointestinal system symptoms (67.2%, N = 45), among them abdominal pain (80%, n = 36) and diarrhea (64.4%, n = 29). Various rash and conjunctivitis were detected in 26 and 21 patients, respectively. KD-like presentation was found 37.3% of patients (n = 25) in this cohort. Respiratory symptoms were only in five patients in our study. At admission, 31 patients had cardiac abnormalities; among these patients, two have coronary arter dilatation (6.45%), %26.9 (n = 18) of patients had hypotension, among these patients 15 patients had myocarditis and/or pericarditis. The median left ventricular ejection fraction (LVEF) was 67% (IQR, 62.2–70.7%). 7.5% of the patients had mild-moderate cardiac dysfunction, which was defined as the depletion of the LVEF (30–50%) at the time of admission. Demographic and clinical findings were presented in Table 1. The patients with cardiac pathologies were found older (median age was 11.25 vs 5.5 years, p = 0.04) Cardiac involvements were found similar both gender (p = 0.33). Among the presenting symptoms, the presence of conjunctivitis was found to be associated with cardiac findings, while gastrointestinal, rash, and long fever duration (>4 days) were not found to be statistically significance (p = 0.04 vs p = 0.53, p = 0.13, and p = 0.45, respectively). High levels of neutrophil lymphocyte ratio were detected in the patients with cardiac pathologies (9.5 ± 7.3 vs 6.2 ± 5.8, p = 0.04).

Most patients (n = 52 (77.6%)) tested positive only for SARS-CoV-2 antibody; 9 (13.4%) tested positive for both RT-PCR and antibodies, and 6 patients (18%) were accepted contact. The median white blood cell count was found 10,040/mL (IQR, 7080–14,780 /mL), lymphocyte was 1390 (IQR, 870–2260) and neutrophile lymphocyte ratio was (NLR) 5.3 (IQR, 2.4–11).

Table 1. Demographic and clinical characteristics of patients.

| Demographic Characteristics | Total (n = 67) |
|-----------------------------|---------------|
| Gender (F/M)                | 19/48         |
| Age (mean±SD)              | 9 ± 5.2       |
| Follow up duration (median (IQR)) | 3 (1.5–3)     |
| Comorbid diseases (n%)      | n %           |
| Obesity                     | 9 13.4        |
| Autoimmune or autoinflammatory disease | 6 8.9 |
| Immunodeficiency            | 2 3           |
| epilepsy                    | 2 3           |
| Clinical findings (n%)      | n %           |
| Fever                       | 67 100        |
| Fever >4 days               | 40 59.7       |
| Duration of fever (mean-min-max) | 4.4 (1–15)    |
| Abdominal pain              | 36 53.7       |
| Diarrhea                    | 29 43.2       |
| Various rash                | 26 38.8       |
| Conjunctivitis              | 21 31.3       |
| KD- like presentation       | 25 37.3       |
| Respiratory symptoms        | 5 7.4         |
| Hypotension                 | 18 26.8       |
| Altered consciousness       | 5 7.5         |
| Myocarditis and/or pericarditis | 15 22.3   |
| Mild-moderate cardiac dysfunction | 5 7.5   |
The median C reactive protein (CRP) was 13.2 mg/dL (IQR, 17.9–20.4 mg/dL), and ferritin 340.7 ng/mL (IQR, 201–671 ng/mL). The median troponin was 0.005 ng/mL(IQR, 0.003–0.044 ng/mL) and brain natriuretic peptide (BNP) 228 pg/mL (IQR, 87.5–1296 pg/mL). The median d-dimer was 2380 mg/mL (IQR, 1255–4127 mg/mL). Hyponatremia and hypoalbuminemia were detected in 46.3% of patients (n = 31). Macrophage activating syndrome was detected in 15 patients (22.4%). We measured IL-6 level in 20 patients, the median IL-6 levels were found 45.5 (IQR, 11.7–197.5) pg/mL. Laboratory characteristics of patients are shown in Table 2.

The mean duration of hospitalization was 11.8 ± 7.07 days (min-max: 1–37 days). Fifty-seven patients (85%) received intravenous immunoglobulin (IVIG) and 45 (67%) received corticosteroids (median 23 days). The first IVIG dose (2 g/kg) was administered in 24 hours to 70% of the patients, and 20 of these patients were given concurrent steroids. 17 (25.3%) patients received anakinra (median 8 days), and one (1.5%) received tocilizumab (10 mg/kg). The median (IQR) dose of anakinra was 3 mg/kg/day (IQR, 2–4 mg/kg/day). Seven of the patients (10.4%) underwent extracorporeal plasma exchange (EPE). Vasoactive medications mostly used norepinephrine were used in 14 patients (21%). The median duration of vasopressor use was 5 days (IQR, 1–6 days). Prophylactic dosing with enoxaparin was used in 42 (63%) patients. The median duration of anticoagulant use was 7.5 days (IQR, 3.75–11).

In 21 (31.3%) patients, a pediatric intensive care unit (PICU) was required within a median of 2 days, of which two patients (9.5%) required invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Nineteen patients were discharged from PICU with an average stay of 4.7 days (IQR, 4–8 days) and two patients (3%) died (Table 2). The patients who needed a PICU were older than others (11 vs 8 years, p = 0.04). The presence of rash, bradycardia, hypoalbuminemia and high levels of N/L ratio was noted in patients who needed intensive care and biologic therapy (Table 4). Therefore, the patients who treated only IVIG were younger than other (median 4.75 years vs 11.2 years).

During the hospitalization period, the first finding to improve was fever, while the first parameter to decrease was ferritin (median 6.5 days (IQR, 4–11.2 days)). The recovery time of other laboratory parameters is in Table 3. Sixty-five patients were discharged home with a median duration of hospital stay of 10 days (IQR, 7–15 days).

### Post-Discharge Follow-Up

All patients were invited to outpatient clinic control within the first 2 weeks for clinical evaluation, and management of therapy (steroid and anticoagulant). Patients came to the first outpatient clinic on the median 11th day. Lymphopenia was detected in three patients, elevated ferritin in four patients and elevated d-dimer was in three patients. After the first control, all patients who received prophylactic heparin treatment were discontinued and aspirin was started. 26 of 31 (84%) patients with cardiac pathology improved during follow-up. While coronary artery (CA) dilatation continued in two patients, and mitral valve insufficiency persisted in one patient.

| Table 4. Comparison of clinical and laboratory indicators in patients based on the anakinra treatment and intensive care hospitalization. |
|---------------------------------|-----------------|-----------------|
| **PICU Admission** | **Anakinra therapy** |
| Age (months)* | Present (n = 21) | Absent (n = 46) | p | Present (n = 17) | Absent (n = 50) | p |
| NLR | 13.0 | 5.31 | 0.00 | 9.4 | 4.2 | 0.00 |
| Hyponatremia (n/%) | 16/76.1 | 15/32.6 | 0.01 | 14/82.3 | 17/34 | 0.00 |
| Bradycardia (n/%) | 8/38 | 0/0 | 0.00 | 7/41.1 | 1/2 | 0.00 |
| Myocarditis (n/%) | 13/61.9 | 10/21.7 | 0.02 | 8/47 | 15/30 | 0.16 |
| Rash (n/%) | 12/57.1 | 14/66.6 | 0.03 | 11/64.7 | 15/30 | 0.01 |
| Hypoalbuminemia (n/%) | 20/95.2 | 11/52.3 | 0.00 | 16/94.1 | 11/22 | 0.00 |

*median, PICU: Pediatric intensive care unit, NLR: Neutrophil/Lymphocyte ratio
Table 3. Recovery features and normalization period of laboratory findings of patients$^{*}$.

| Parameter                      | Median (IQR) |
|--------------------------------|--------------|
| Ferritin                       | 6.5 (4–11.2) |
| Neutrophil Lymphocyte Ratio    | 7 (3–10)     |
| Lymphocyte                     | 5 (3–7)      |
| D-Dimer                        | 7 (4.75–12)  |
| C Reactive Protein             | 10 (7–13)    |
| Brain Natriuretic Peptide      | 10 (10–19.5) |

*The period (days) for laboratory parameters to return to their normal range of from the start of treatments (median – IQR).

Discussion

In this study, we aim to present our disease findings and treatment results in a large cohort of patients with a diagnosis of MIS-C. Consistent with the literature, the patients were children in the 7–8 age group, who were previously healthy, and there was male gender predominance [2,3,15,19–21].

The majority of patients (61 [91%]) were tested positive for SARS-CoV-2 infection by RT-PCR, antibody testing, or both. Six (9%) patients had an epidemiologic link to a person with Covid-19. In our study, the number of patients diagnosed only with epidemiological connection was lower than in other reported case series (30% in Feldstein et al, 27% in Dhanalakshmi et al. and 34% in Jain et al. series) [3,22,23]. We think that the presence of laboratory evidence is very important to avoid overdiagnosis. Since other infections were rarely seen during the pandemic period in our daily practice, a small number of patients whose clinical findings fully overlap with MIS-C were diagnosed with only an epidemiological link. In our series, 13.4% of children had RT-PCR positive, among these five patients has symptomatic COVID infection previously. In such patients it is necessary to distinguish between MIS-C and severe COVID infections. Feldstein et al. showed that findings such as cardiovascular or mucocutaneous rash are more common than respiratory symptoms in MIS-C [3].

The most common comorbidities reported in previous reports are being overweight (10–39%) and previous asthma history (5–18%) [2,8,19,20]. In our patient group, obesity was detected in 13.4% of patients. In addition, four of our patients used biological therapy due to various rheumatic diseases (such as juvenile idiopathic arthritis, deficiency of Adenosine deaminase enzyme –2) and one patient was diagnosed with immunodeficiency (Costman syndrome).

Initial clinical findings in patients with a diagnosis of MIS-C vary widely, high fever is often accompanied by gastrointestinal system dermatological and cutaneous pathologies [2,3,15,19–21,24,25]. In our reported patient group, abdominal pain was observed as the most common finding accompanying high fever. Mesenteric lap, severe diarrhea and vomiting, which may be bloody, were observed as other gastrointestinal system symptoms.

The prevalence of KD is significantly higher in East Asian countries, including Japan, Korea, China and Taiwan, but low in Europe and the USA [26,27]. In previous studies, especially involving European cohorts, most MIS-C patients were reported to have KD-like symptoms [8,28–31]. In other study from Turkey was reported 63.6% of 33 patients with MIS-C had KD-like syndrome (26). In contrast with these studies, KD-like presentation was found 37.3% of patients in our cohort. In the pathogenesis of both MISC and KD; abnormal or dysregulated immune reactions, and the release of large amounts of inflammatory cytokines (cytokine strome) can lead to similar clinical pictures in both diseases [12,32,33]. Considering our clinical observations and the literature, it suggests that both diseases are different entities. MIS-C patients have more specific features that are not present in patients with KD; especially severe abdominal pain mimicking acute appendicitis, bradycardia, myocardial involvement and lymphopenia, high pro-BNP and D-dimer levels.

In our cohort, 31.3% of patients required PICU admission, median 2 days. Nineteen patients were discharged from PICU with an average stay of 4.7 days (IQR, 4–8 days) and two patients (3%) died. In our cohort, the PICU requirement was higher than in both the Latin American (12.7%) and European cohorts (8%), and the mortality rate was like the Latin American cohort (4.2%) [10,19]. The percentage of patients admitted PICU 67% and 80% in the largest French and U.S. studies, respectively [3,34].

Looking at other studies, overall higher rates of serious illness and death have been reported in patients and their family members with economic and insurance instability, rough work, and home environments [4,19]. In our study, the risk factors associated with need of PICU admission were reported as older age, bradycardia, myocarditis, hyponatremia and/or hypoalbuminemia. Abrams et al. series decreased cardiac function, shock, and myocarditis was associated with PICU admission [35].

Cardiac involvement begins with bradycardia/hypotension and may end with myocardial dysfunction and cardiogenic shock [2,3,15,21,24,28,34,36]. In the reported patient groups, the frequency of left ventricular dysfunction is between 31% and 100% [37]. In a study by Kaushik et al., it was reported that 97% of the patients had an echocardiogram and the depressed LV ejection fraction (<50%) was 65% [15]. The possible mechanisms of myocardial damage in MIS-C include acute viral myocarditis, inflammation, hypoxia, stress cardiomyopathy, and ischemia due to CA involvement, which is rare compared to others [37]. In our cohort, myocarditis and/or pericarditis was seen in 27 patients, %52 of the patients (n = 14) progressed myocardial dysfunction and required inotropic agents in PICU. Two patients were needed ECMO support. The use of inotropic support in our cohort was lower than that reported by Belhadjer et al. in a cohort of 35 children in which 80% of patients had inotropic support [38]. The length of PICU stay of MIS-C cases was 4.7 days, which is similar to the Özsurekçi et al. report [25].

In the literature, rhythm abnormalities of varying severity have been described in 7–60% of patients, and coronary artery enlargement or aneurysms in 6–24% [37]. In our cohort, bradycardia occurring 2 days after the median hospitalization in 11 (16.4%) patients, coronary artery enlargement was observed in two patients. In our patient group, bradycardia was mostly observed in the adolescent age group. With this
determination, we think that closer monitoring of rhythm problems of patients at this age will positively affect the treatment outcome. This result needs to be confirmed by larger cohort studies.

Recovery of cardiac pathologies occurred in %84 of our cohort at hospital discharge. This result was found in report of Kausik et al. (95%) and in Belhadjer et al. (71%) [15,38]. The median recovery time was 8.5 days (IQR,5.5–17.7 days).

A standard clinical practice guideline for MIS-C therapy has been proposed by the American College of Rheumatology (ACR). According to this guideline, ACR has recommended the use of IVIG and/or corticosteroids as first-line therapy in these patients [39,40]. Approximately 30–80% patients do not respond to IVIG alone and may require adjunctive immuno-modulatory therapy to control inflammation. The efficiency of IVIG treatment alone has been reported to be 30–80% in studies [28,33,34,41–44].

In the same guideline, high-dose anakinra (recombinant IL-1 receptor antagonist) (>4 mg/day) is recommended for MIS-C patients with resistant disease despite receiving IVIG and steroid therapy (34). Due to increased IL-6 levels and adverse outcomes in COVID-19, IL-6 neutralization with tocilizumab is also among the treatments applied [45]. Diorio et al. reported that serum IL-1, IL-2, and IL-6 levels were elevated in patients with MIS-C [46]. IVIG resistance was found 55.2% of our patients, which was higher than KD that reported by Pilania et al [47]. In our study, IVIG resistant patients were older (median age 8.87 vs 10 years, p = 0.2). When the relationship between clinical findings at presentation and IVIG resistance and anakinra requirement was evaluated, a significant relationship was observed with cutaneous findings (p = 0.004 and P = 0.006, respectively). We treated 17 (25.3%) patients with anakinra, and one (1.5%) received tocilizumab before anakinra. This patient was currently followed up with a diagnosis of systemic JIA. After MIS-C developed, he was given tocilizumab first after IVIG and steroid because he also had pulmonary findings. He had high IL-6 levels (178 pg/ml). However, since there was no response to this treatment, TPE was performed in addition to high-dose anakinra (10 mg/kg/day).

TPE reduces mortality in serious and/or life-threatening MIS-C patients by reducing cytokines. In the report presented by Emekziz et al., TPE was reported to decrease mortality [48]. In our population, TPE was applied to 10.4% of patients.

Diorio et al. reported increases in markers of endothelial dysfunction and vascular injury in MIS-C with elevated d-dimers and B-natriuretic proteins [46]. Per institutional protocols, MIS-C patients s would have received prophylactic anticoagulation [49,50]. We treated 45 (63%) patients with prophylactic enoxaprin during the symptomatic period and continued treatment with aspirin for 1 month after recovery. We terminated the treatment of the patient who did not have dimer elevation or signs of thrombosis in the control. Guidelines regarding the thrombotic evaluation and anticoagulation management of hospitalized children with MIS-C remains lacking [51].

In a systematic review by Kaushik et al. the median duration of hospitalization was 7 days, and intensive care was required in 68% of patients [13]. The mortality rate was reportedly 1.7% in the US and 1.4% in Europe [15]. Capone et al reported cardiac involvement experienced nearly full recovery [16]. The long-term prognosis of MIS-C is unknown as there are not many studies on the subject. In the follow-up results of the patients who were followed up for a median of 3 months in our study; median duration hospitalization was found 10 days and mortality rate was 2.9%. Majority of patients with cardiac involvement (84%) improved during follow-up. It was observed that coronary dilatation improved in one of our patients after 17 days and in the other after 110 days. These results show that MIS-C, which has a frightening course in clinical follow-up, does not cause permanent damage in most patients with appropriate treatment. Of course, this result needs to be confirmed in large cohorts.

Conclusions

In conclusion, patients in our cohort showed clinical features like KD or MAS, like as hundreds of patients with MIS-C diagnosed during the COVID-19 outbreak. Although these patients had severe cardiac findings and intensive care requirements, they recovered until their discharge and were followed up in the short term without any sequelae. Although the pathogenesis and treatment plan of the disease are partially elucidated, follow-up studies are needed in terms of long-term prognosis and relapse probabilities.

Acknowledgments

We are grateful to all participating children and their families.

Author contributions

Conception and design; BS, ŞÇ, VA, KU, TÇ, ÖPA, CHA, GA, ES, MK, TO, SE and FD, Analysis and interpretation of the data; BS and FD, Drafting of the paper or revising it critically for intellectual content; BS and FD, The final approval of the version to be published; BS, ŞÇ, VA, KU, TÇ, ÖPA, CHA, GA, ES, MK, TO, SE and FD, and all authors agree to be accountable for all aspects of the work.

ORCID

Betül Sözeri http://orcid.org/0000-0002-5079-5644
Kadir Ulu http://orcid.org/0000-0002-8197-6077
Ferhat Demir http://orcid.org/0000-0001-9801-925X

References

1. Hoang A, Chorath K, Moreira A, et al. Covid-19 in 7780 Pediatric Patients: a Systematic Review. E Clinical Medicine. 2020;24. 100433.
2. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020;383 (4):347–358.
3. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020;383 (4):334–346.
4. Godfred-Cato S, Bryant B, Leung J, et al. Covid-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. Morb Mortal Wkly Rep. 2020;69(32):1074–1080.
5. Jiang L, Tang K, Levin M, et al. Covid-19 and Multisystem Inflammatory Syndrome in Children and Adolescents. Lancet Infect Dis. 2020;20(11):E276–288.
22. Diorio C, Henrickson SE, Vella LA, et al. Multisystem Inflammatory Syndrome in Children and Covid-19 are Distinct Presentations of Sars-Cov-2. J Clin Invest. 2020;130(11):5967–5975.

23. Rubens JH. Acute Covid-19 and Multisystem Inflammatory Syndrome in Children. BMJ. 2021;372:n385.

24. Whitaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated with Sars-Cov-2. JAMA. 2020;324(3):259–269.

25. Kwak JH, Lee YS. Clinical Features, Diagnosis, and Outcomes Of Multisystem Inflammatory Syndrome in Children Associated with Corona Virus Disease 2019. Clin Exp. 2021;64:68–75.

26. Götzinger F, Santiago-Garcia B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653–661.

27. Bagri NK Hemophagocytic Lymphohistiocytosis: manifestation of an unamed immune system. Indian J Pediatr [Internet]. 2020 May 26 [cited 2020 May 29]; 67 7:493–494.

28. Rowley AH. Understanding Sars-Cov-2-Related Multisystem Inflammatory Syndrome in Children. Nat Rev Immunal. 2020;20(8):453–454.

29. Perlman S, Dandekar AA. Immunopathogenesis Of Coronavirus Infections: implications for Sars. Nat Rev Immunal. 2005;5(12):917–927.

30. Lamers M, Beumer J, Vaart JVD, et al. Sars-Cov-2 Productively Infects Human Gut Enterocytes. Science. 2020;369(6499):50–54.

31. Kaushik S, Aydin SI, Deresina KR, et al. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Sars-Cov-2 Infection: a Multi-Institutional Study From New York City. J Pediatr. 2020;224:24–29.

32. Ca C, Subramony A, Sweberg T, et al. Characteristics, Cardiac involvement, and outcomes of Multisystem inflammatory syndrome of Childhood associated with severe Acute respiratory syndrome coronavirus 2 infection. J Pediatr. 2020;224:141–145.

33. Demir F, Uluk, S, Ç, et al. Clinical Course Of Covid-19 in Children With Rheumatic Disease Under Biologic Therapy. Clin Exp Rheumatol. 2021;128:36–37.

34. Centers For Disease Control And Prevention, Multisystem in Flammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease 2019 (Covid-19) [Internet]. Atlanta (Ga): Centers For Disease Control And Prevention; [cited 2020 July 10] Available From: https://Emergency.Cdc.Gov/Han/2020/Han00432.Xml

35. Antúnez-Montes OY, Escamilla MI, Figueroa-Uribé AF, et al. COVID-19 and Multisystem Inflammatory Syndrome in Latin American children: a Multinational Study. Pediatr Infect Dis J. 2021;40(1):e1–66.

36. Lee PY, Day-Lewis M, Henderson LA, et al. Distinct Clinical and Immunological Features Of Sars-Cov-2-Induced Multisystem Inflammatory Syndrome in Children. J Clin Invest. 2020;130(11):5942–5950.

37. Moraleda C, Serna-Pascual M, Soriano-Arandes A, et al. Multisystem inflammatory Syndrome in Children Related To Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-CoV-2) in Spain. Clin Infect Dis. 2020. DOI:10.1093/Cid/Ciaa1042.

38. Dhanalakshmi K, Venkatakrishan A, Balasubramanian S, et al. Epidemiological and Clinical Profile of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS) in Indian Children. Indian Pediatr. 2020;57(11):1010–1014.

39. Jain S, Sen S, Lakshminivakshesh S, et al. Multisystem Inflammatory Syndrome in Children With COVID-19 in Mumbai, India. Indian Pediatr. 2020;57(11):1015–1019.

40. Rafferty MS, Burrows H, Joseph JP, et al. Multisystem Inflammatory Syndrome in Children (MIS-C) and the Coronavirus Pandemic: current Knowledge and Implications for Public Health. J Infect Public Health. 2021;14(4):484–494.

41. Ozsureky C, Gürlevik S, Kesiçi S, et al. Multisystem Inflammatory Syndrome in Children During The Covid-19 Pandemic iTurkey: first Report From The Eastern Mediterranean. Clin Rheumatol. 2021;12:1–11.

42. Mc Crindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: a Scientific Statement For Health Professionals From The American Heart Association. Circulation. 2017;135:E927–99.

43. Kim GB, Park SH, Eun LY, et al. Epidemiological and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. Pediatr Infect Dis J. 2017;36(5):482–485.

44. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-Like Multisystem Inflammatory Syndrome in Children During The Covid-19 Pandemic Paris, France: prospective Observational Study. BMJ. 2020;369:m2094.

45. Radia T, Williams N, Agrawal P, et al. Multisystem Inflammatory Syndrome in Children & Adolescents (MIS-C): a Systematic Review Of Clinical Features And Presentation. Paediatr Respir Rev. 2020;1526-0542.2–30117.

46. Godfred-Cato S, Bryant B, Leung J, et al. Covid-19-Associated Multisystem Inflammatory Syndrome in Children - United States, March-July 2020. Morb Mortal Wky Rep. 2020;69(32):1074–1080.

47. Çelikel E, Tekin ZE, Aydin F, et al. Role of Biological Agents in The Treatment of Sars-Cov-2 associated Multisystem Inflammatory Syndrome in Children. J Clin Rheumatol. 2021;Publish Ahead Of Print. DOI:10.1097/RHU.0000000000001734.

48. Raba AA, Abobaker A. Covid-19 and Kawasaki Disease: an Etiology Or Coincidental Infection? Pediatr Infect Dis J. 2020;39(8):E213.

49. Kabeeross J, Pilania RK, Karkhele R, et al. Severe COVID-19, multi-system inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. Rheumatol Int. 2021;41:19–32.

50. Belot A, Antona D, Renoleon S, et al. SARS-CoV-2-related paediatric multisystem inflammatory syndrome, an epidemiological study, France, 1 March to 17 May 2020. Euro Surveill. 2020;25(22). 10.2807/1560-7917.ES.2020.25.22.2001010.

51. Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021;5(5):322–331.

52. Grimaud M, Starck J, Levy M, et al. Acute Myocarditis and Multisystem Inflammatory Emerging Disease Following SarcoV-2 Infection in Critically Ill Children. Ann Intensive Care. 2020;10(1):69.

53. Sperotto F, Friedman KG, Son MBF, et al. Cardiac Manifestations in Sars-CoV-2-Associated Multisystem Inflammatory Syndrome in Children: a Comprehensive Review And Proposed Clinical Approach. Eur J Pediatr. 2021;180(2):307.

54. Belhdar Z, Méot M, Bajolle F, et al. Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context Of Global Sars-CoV-2 Pandemic. Circulation. 2020;42(5):429–436.

55. Henderson LA, Canna SW, Friedman KG, et al. American College Of Rheumatology Clinical Guidance For Multisystem Inflammatory Syndrome in Children Associated with Sars-Cov-2 And Hyperinflammation In Pediatric COVID-19: version 1. Arthritis Rheumatol. 2020;72(11):1791–1805.

56. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance For Multisystem Inflammatory Syndrome children Associated with Sars-Cov-2 And Hyperinflammation in Pediatric COVID-19: version 2. Arthritis Rheumatol. 2021;73(4):E13–E29.

57. Poulletty M, Borocco C, Ouldali N, et al. Paediatric Multisystem Inflammatory Syndrome Temporally Associated with Sars-CoV-2 Mimicking Kawasaki Disease (Kawa-Covid-19): a Multicentre Cohort. Ann Rheum Dis. 2020;79(8):999–1006.

58. Cheung E, Zachariah P, Gorelik M, et al. Multisystem Inflammatory Syndrome Related To Covid-19 in Previously Healthy Children And Adolescents (CIRS). New York City. JAMA. 2020;324(3):294–296.

59. Ramcharan T, Nolan O, Lai CY, et al. Paediatric Inflammatory Multisystem Syndrome: temporally Associated with Sars-CoV-2 (Pims-Ts): cardiac Features, Management And Short-Term Outcomes at a Uk Tertiary Paediatric Hospital. Pediatr Cardiol. 2020;41(7):1391–1401.

60. Nakra NA, Blumberg DA, Herrera-Guerra A, et al. Multi-System Inflammatory Syndrome in Children (MISC) Following Sars-CoV-2
Infection: review Of Clinical Presentation, Hypothetical Pathogenesis, And Proposed Management. Child Basel Switz. 2020;7:69.

45. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.

46. Diorio C, Henrickson SE, Vella LA, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. J Clin Invest. 2020;130(11):5967–5975.

47. Pilania R, Jindal A, Guleria S, et al. An Update On Treatment Of Kawasaki Disease. Curr Treat Opt Rheumatol. 2019;5(1):36–55.

48. Emeksz S, Özcan S, Perk O, et al. Therapeutic Plasma Exchange: a Potential Management Strategy For Critically Ill MIS-C Patients in The Pediatric Intensive Care. Unit.Transfus Apher Sci. 2021;1(3):103119.

49. Elias MD, McCrindle BW, Larios G, et al. of the International Kawasaki Disease Registry. Management of Multisystem Inflammatory Syndrome in Children Associated With COVID-19: a Survey From the International Kawasaki Disease Registry. CJC Open. 2020;2(6):632–640.

50. Goldenberg NA, Sochet A, Albisetti M, et al. Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee of the ISTH SSC. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost. 2020;18 (11):3099–3105.

51. Bansal N, Azeka E, Neunert C, et al. Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action. Pediatr Cardiol. 2021;42:1635–9